Accelerating General Anesthetic Discovery and Mechanisms Research with Zebrafish
加速斑马鱼全身麻醉的发现和机制研究
基本信息
- 批准号:9983104
- 负责人:
- 金额:$ 37.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-08-01 至 2021-07-31
- 项目状态:已结题
- 来源:
- 关键词:Academic Medical CentersAdrenergic ReceptorAffectAgeAmnesiaAnestheticsBiological AssayBostonCRISPR/Cas technologyClinicalComputer softwareDataData AnalysesDevelopmentDiseaseDrug KineticsDrug ScreeningDrug TargetingElectrophysiology (science)EquipmentFishesGene MutationGeneral AnesthesiaGeneral anesthetic drugsGeneticGlycine ReceptorsGoalsHCN1 geneHypnosisImmobilizationIntravenousIntravenous AnestheticsIon ChannelKnock-inKnock-outKnockout MiceLarvaLeadLearningLibrariesLinkMeasuresMediatingMedicineModelingModern MedicineModernizationMolecularMolecular StructureMolecular TargetMotionMutationN-Methyl-D-Aspartate ReceptorsN-MethylaspartateNervous system structureNeurobiologyNeuronsPainPatient CarePatientsPharmaceutical PreparationsPharmacodynamicsPharmacologyPhenotypePlayProbabilityProceduresPropertyRattusReflex actionResearchResponse to stimulus physiologyRiskRoleSedation procedureSeriesSiteSprague-Dawley RatsStimulusStructureStructure-Activity RelationshipTadpolesTestingTransgenic OrganismsUniversitiesVariantVulnerable PopulationsXenopusZebrafishbasedrug mechanismexperimental analysisexperimental studyhypnoticimprovedinhibitor/antagonistintravenous administrationmolecular modelingmutantneurobiological mechanismnovelnovel strategiesnovel therapeuticsreceptorresponsescale upsedativeside effectsuccesstoolvoltage clamp
项目摘要
ABSTRACT: General anesthesia is essential for modern procedural medicine. There is a compelling need to
find superior alternatives to current sedative-hypnotics, which derive from a few drug classes identified before
1980, and also cause undesirable or harmful side effects, especially in vulnerable populations. To date,
strategies to discover new anesthetics are based on molecular models, mostly GABAA receptors, that are
targets for a few potent intravenous hypnotics. Our long-term goals are to identify new sedative-hypnotic
chemotypes that may improve patient care, while also advancing molecular and neurobiological research on
anesthetic mechanisms. We hypothesize that a wide variety of undiscovered potent sedative-hypnotic
chemotypes exists. These may modulate GABAA receptors through several known sites, or act through other
known or perhaps unknown mechanisms. Our novel strategy uses concurrent video motion analysis of up to
96 zebrafish larvae as a high-throughput un-biased stimulus-response test platform to accelerate discovery
and characterization of new potent sedative-hypnotics. Zebrafish larvae immersed in solutions of non-volatile
drugs rapidly establishes steady-state conditions for assessing pharmacodynamic effects. Combining this
approach with new transgenic zebrafish lines harboring mutations that alter or eliminate known and
suspected general anesthetic targets in the nervous system will also accelerate exploration of molecular
and neurobiological mechanisms. In Aim 1, we will use video analysis tools to assess both baseline motion
and photomotor response probability in up to 96 zebrafish larvae simultaneously. We have developed robust
experimental and data analysis approaches to both screen for new sedative-hypnotics and determine sedative
and hypnotic potencies (Aim 1a). We already have identified several potent active lead compounds in a drug
library from the Boston University Center for Medical Discovery (BUCMD). New active leads will also be tested
for activity/potency in both tadpoles and rats (Aim 1b). Collaborators at BUCMD will also synthesize structural
variants of selected lead compounds, enabling exploration of structure-activity relationships for sedation and
hypnosis in zebrafish, as illustrated in preliminary data (Aim 1c). In Aim 2, we will explore the molecular
mechanisms of new sedative-hypnotics using voltage-clamp electrophysiology in a panel of heterologously
expressed ion channels (GABAARs, GlyRs, NMDA-Rs, neuronal nAChRs, HCN1 and TREK-3) or
antipamezole antagonism of α2 adrenergic receptors (Aim 2a). Sedative-hypnotics that potentiate GABAARs,
will also be tested in a series of receptor mutants to assess selectivity for known subsites (Aim 2b). In Aim 3,
we will use CRISPR-Cas9 to create transgenic zebrafish lines for testing the roles of drug targets in sedation
and hypnosis. We will first create a panel of GABAAR subunit knock-out and knock-in lines (Aim 3a; β3 and δ
KOs are made). We will also make knockouts for HCN1 (already made), TREK-3, K2P and α2 AdRs (Aim 3b).
Sedative and hypnotic potencies of known and novel drugs will be compared in mutant vs. wild-type zebrafish.
摘要:全身麻醉是现代手术医学的基础。迫切需要
找到比目前的镇静催眠药更好的上级替代品,这些替代品来自以前确定的几类药物
1980年,也造成不良或有害的副作用,特别是在弱势群体中。到目前为止,
发现新麻醉剂的策略基于分子模型,主要是GABAA受体,这些模型是
几种强效静脉注射催眠药的靶点我们的长期目标是找出新的镇静催眠药
化学型,可以改善病人的护理,同时也推进分子和神经生物学研究,
麻醉机制我们假设有多种未被发现的强效镇静催眠药
存在化学型。这些可以通过几个已知的位点调节GABAA受体,或通过其他途径起作用。
已知或未知的机制。我们的新策略使用并发视频运动分析高达
96斑马鱼幼虫作为高通量无偏刺激反应测试平台,以加速发现
和新型强效镇静催眠药的特性。斑马鱼幼虫浸泡在非挥发性的
药物快速建立用于评估药效学效应的稳态条件。组合该
方法与新的转基因斑马鱼线窝藏突变,改变或消除已知的,
神经系统中疑似全身麻醉靶点的发现也将加速对分子麻醉的探索。
和神经生物学机制。在目标1中,我们将使用视频分析工具来评估基线运动
和光运动反应概率在多达96斑马鱼幼虫同时。我们开发了强大的
实验和数据分析的方法来筛选新的镇静催眠药和确定镇静剂
催眠作用(Aim 1a)我们已经在一种药物中发现了几种有效的活性先导化合物
Boston University Center for Medical Discovery(BUCMD)还将测试新的有源电极导线
在蝌蚪和大鼠中的活性/效力(目标1b)。BUCMD的合作者还将合成结构
所选先导化合物的变体,能够探索镇静和
催眠在斑马鱼,如初步数据所示(目标1c)。在目标2中,我们将探索分子
在一组异源性神经元中使用电压钳电生理学研究新镇静催眠药的机制
表达的离子通道(GABAAR、GlyR、NMDA-R、神经元nAChR、HCN 1和TREK-3)或
α2肾上腺素能受体拮抗剂(Aim 2a)。增强GABAAR的镇静催眠药,
还将在一系列受体突变体中进行测试,以评估对已知亚位点的选择性(目标2b)。在目标3中,
我们将使用CRISPR-Cas9来创建转基因斑马鱼系,以测试药物靶点在镇静中的作用。
还有催眠我们将首先建立一组GABAAR亚基敲除和敲入系(Aim 3a; β3和δ
制造科斯)。我们还将敲除HCN 1(已制备)、TREK-3、K2 P和α2 AdR(Aim 3b)。
将在突变型与野生型斑马鱼中比较已知和新型药物的镇静和催眠效力。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STUART A FORMAN其他文献
STUART A FORMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STUART A FORMAN', 18)}}的其他基金
Basic and Translational Research on General Anesthetics
全身麻醉的基础与转化研究
- 批准号:
10395548 - 财政年份:2021
- 资助金额:
$ 37.99万 - 项目类别:
Basic and Translational Research on General Anesthetics
全身麻醉的基础与转化研究
- 批准号:
10206422 - 财政年份:2021
- 资助金额:
$ 37.99万 - 项目类别:
Basic and Translational Research on General Anesthetics
全身麻醉的基础与转化研究
- 批准号:
10599115 - 财政年份:2021
- 资助金额:
$ 37.99万 - 项目类别:
General Anesthetic Sites in GABA-A Receptor Subunit Interfacial Pockets
GABA-A 受体亚基界面袋中的全身麻醉位点
- 批准号:
9975188 - 财政年份:2010
- 资助金额:
$ 37.99万 - 项目类别:
General Anesthetic Sites in GABA-A Receptor Subunit Interfacial Pockets
GABA-A 受体亚基界面袋中的全身麻醉位点
- 批准号:
9312844 - 财政年份:2010
- 资助金额:
$ 37.99万 - 项目类别:
General Anesthetic Sites in GABA-A Receptor Subunit Interfacial Pockets
GABA-A 受体亚基界面袋中的全身麻醉位点
- 批准号:
8775923 - 财政年份:2010
- 资助金额:
$ 37.99万 - 项目类别:
General Anesthetic Sites in GABA-A Receptor Subunit Interfacial Pockets
GABA-A 受体亚基界面袋中的全身麻醉位点
- 批准号:
8510665 - 财政年份:2010
- 资助金额:
$ 37.99万 - 项目类别:
General Anesthetic Sites in GABA-A Receptor Subunit Interfacial Pockets
GABA-A 受体亚基界面袋中的全身麻醉位点
- 批准号:
8136477 - 财政年份:2010
- 资助金额:
$ 37.99万 - 项目类别:
General Anesthetic Sites in GABA-A Receptor Subunit Interfacial Pockets
GABA-A 受体亚基界面袋中的全身麻醉位点
- 批准号:
8299577 - 财政年份:2010
- 资助金额:
$ 37.99万 - 项目类别:
General Anesthetic Sites in GABA-A Receptor Subunit Interfacial Pockets
GABA-A 受体亚基界面袋中的全身麻醉位点
- 批准号:
7985708 - 财政年份:2010
- 资助金额:
$ 37.99万 - 项目类别:
相似海外基金
Structural basis for regulation of beta2 adrenergic receptor signaling by the dynamic post-translational modification S-palmitoylation
动态翻译后修饰S-棕榈酰化调节β2肾上腺素受体信号传导的结构基础
- 批准号:
10603466 - 财政年份:2023
- 资助金额:
$ 37.99万 - 项目类别:
Modulation of T lymphocyte Activation by Ã2-Adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
RGPIN-2019-06980 - 财政年份:2022
- 资助金额:
$ 37.99万 - 项目类别:
Discovery Grants Program - Individual
Glucocorticoid and Adrenergic Receptor Signaling at the Neuroimmune Interface
神经免疫界面的糖皮质激素和肾上腺素能受体信号传导
- 批准号:
RGPIN-2019-04706 - 财政年份:2022
- 资助金额:
$ 37.99万 - 项目类别:
Discovery Grants Program - Individual
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574979-2022 - 财政年份:2022
- 资助金额:
$ 37.99万 - 项目类别:
University Undergraduate Student Research Awards
Angiotensin-(1-7) and beta adrenergic receptor signaling in aging
衰老过程中血管紧张素 (1-7) 和 β 肾上腺素受体信号传导
- 批准号:
10448574 - 财政年份:2022
- 资助金额:
$ 37.99万 - 项目类别:
Angiotensin-(1-7) and beta adrenergic receptor signaling in aging
衰老过程中血管紧张素 (1-7) 和 β 肾上腺素受体信号传导
- 批准号:
10629280 - 财政年份:2022
- 资助金额:
$ 37.99万 - 项目类别:
Novel regulation of beta-adrenergic receptor function by phosphoinositide 3-kinase
磷酸肌醇 3-激酶对 β-肾上腺素能受体功能的新调节
- 批准号:
10591688 - 财政年份:2022
- 资助金额:
$ 37.99万 - 项目类别:
Modulation of T lymphocyte Activation by Ã2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574984-2022 - 财政年份:2022
- 资助金额:
$ 37.99万 - 项目类别:
University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574985-2022 - 财政年份:2022
- 资助金额:
$ 37.99万 - 项目类别:
University Undergraduate Student Research Awards
The molecular mechanism of the crosstalk between the beta-2 adrenergic receptor and chemokine receptors in lymphocytes
淋巴细胞β2肾上腺素受体与趋化因子受体串扰的分子机制
- 批准号:
22K07118 - 财政年份:2022
- 资助金额:
$ 37.99万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




